REG - ValiRx PLC - Issue of options and directors dealings <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

09/02/2018 12:00

RNS Number : 4699E
ValiRx PLC
09 February 2018
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Issue of options and directors dealings
London, UK., 9 February 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces it has awarded options to directors and key management. The options may be exercised at a price of 4 pence per share at any time up until 7 February 2028.
Name of Director
Number of Existing Options*
Option Award
Total number of Options
% of existing share capital
Oliver de Giorgio-Miller
555,000
2,750,000
3,305,000
0.8%
Dr Satu Vainikka
694,000
3,625,000
4,319,000
1.1%
Dr George Morris
597,000
3,125,000
3,722,000
0.9%
Gerry Desler
592,960
3,000,000
3,592,960
0.9%
Kevin Alexander
545,000
2,500,000
3,045,000
0.7%
Others
429,000
2,300,000
2,279,000
0.6%
Total
3,412,960
17,300,000
20,712,960
5.0%
*existing options are exercisable at a price between 43.125p - 125p
The issued share capital of the Company comprises 407,462,717 ordinary shares of 0.1 pence per shares. The table below illustrates the existing equity holdings of the directors:
Name of Director
Total number of shares
% of existing share capital
Oliver de Giorgio-Miller
59,555
0.015%
Dr Satu Vainikka
624,909
0.15%
Dr George Morris
588,287
0.14%
Gerry Desler
541,875
0.13%
Kevin Alexander
104,278
0.026%
Total
1,918,904
0.46%
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray/Jo Turner/Richard Nash
Tel: +44 (0) 20 7213 0880


Beaufort Securities Limited (Broker)
Jon Belliss
Tel: +44 (0) 207 382 8300
Notes for Editors
About ValiRx 
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.It aims to make a significant contribution in "precision" medicine and science, namely toengineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. 
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients. 
The Company listed on the AIM Market of the London StockExchange in October 2006 and trades under the ticker symbol: VAL
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Oliver de Giorgio-Miller
2
Reason for notification

a.
Position/Status
Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
ValiRx Plc
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: GB00BWWYSP41
b.
Nature of the transaction
Grant of options
c.
Price(s) and volume(s)






Price(s) per share
Volume(s)

4p
2,750,000

d.
Aggregated information
- Aggregated Volume
- Price
2,750,000
4p
e.
Date of the transaction
9 February 2018
f.
Place of the transaction
AIM
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Dr Satu Vainikka
2
Reason for notification

a.
Position/Status
Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
ValiRx Plc
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: GB00BWWYSP41
b.
Nature of the transaction
Grant of options
c.
Price(s) and volume(s)






Price(s) per share
Volume(s)

4p
3,625,000

d.
Aggregated information
- Aggregated Volume
- Price
3,625,000
4p
e.
Date of the transaction
9 February 2018
f.
Place of the transaction
AIM
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Dr George Morris
2
Reason for notification

a.
Position/Status
Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
ValiRx Plc
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: GB00BWWYSP41
b.
Nature of the transaction
Grant of options
c.
Price(s) and volume(s)






Price(s) per share
Volume(s)

4p
3,125,000

d.
Aggregated information
- Aggregated Volume
- Price
3,125,000
4p
e.
Date of the transaction
9 February 2018
f.
Place of the transaction
AIM
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Gerry Desler
2
Reason for notification

a.
Position/Status
Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
ValiRx Plc
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: GB00BWWYSP41
b.
Nature of the transaction
Grant of options
c.
Price(s) and volume(s)






Price(s) per share
Volume(s)

4p
3,000,000

d.
Aggregated information
- Aggregated Volume
- Price
3,000,000
4p
e.
Date of the transaction
9 February 2018
f.
Place of the transaction
AIM
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Kevin Alexander
2
Reason for notification

a.
Position/Status
Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
ValiRx Plc
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: GB00BWWYSP41
b.
Nature of the transaction
Grant of options
c.
Price(s) and volume(s)






Price(s) per share
Volume(s)

4p
2,500,000

d.
Aggregated information
- Aggregated Volume
- Price
2,500,000
4p
e.
Date of the transaction
9 February 2018
f.
Place of the transaction
AIM

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCEAFANESSPEFF